Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA +0.30%48 Equity-to-Asset is -2.45 as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.90 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Idorsia ranks worse than 96.11% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Idorsia's Total Stockholders Equity for the quarter that ended in Mar. 2026 was CHF-1,176.6 Mil. Idorsia's Total Assets for the quarter that ended in Mar. 2026 was CHF480.5 Mil.
Therefore, Idorsia's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was -2.45.
The historical rank and industry rank for Idorsia's Equity-to-Asset or its related term are showing as below:
XSWX:IDIA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -2.5 Med: 0.1 Max: 0.63
Current: -2.45
During the past 10 years, the highest Equity to Asset Ratio of Idorsia was 0.63. The lowest was -2.50. And the median was 0.10.
XSWX:IDIA's Equity-to-Asset is ranked worse than 96.11% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs XSWX:IDIA: -2.45
Idorsia (XSWX:IDIA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Idorsia Equity-to-Asset Related Terms
Idorsia Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Idorsia's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Idorsia's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Idorsia's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Idorsia's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Idorsia (XSWX:IDIA) has a Equity-to-Asset of -2.45 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #1360 out of 1415 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Idorsia's Equity-to-Asset too high?
Idorsia's current Equity-to-Asset is -2.45. Based on the distribution chart, Idorsia ranks #1360 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #1360 out of 1415 companies for Equity-to-Asset. This places Idorsia in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Equity-to-Asset is -2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.90, compared to a current price of CHF6.65 — trading 129.3% above its estimated fair value. The current Equity-to-Asset is -2.45. Idorsia's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Equity-to-Asset is -2.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.65 is trading 129.3% above its estimated GF Value™ of CHF2.90.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Equity-to-Asset: -2.45
GF Value™: CHF2.90 vs. price of CHF6.65 (129.3% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
